ArticleJTCVS structural and endovascular2025
Use of balloon-expandable valves for the surgical treatment of mitral valve disease in the setting of severe mitral annular calcification.
Article in JTCVS structural and endovascular, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The treatment of mitral valve disease complicated by severe mitral annular calcification poses a significant challenge, with increased risk of morbidity and mortality. We describe the outcomes after surgical mitral valve replacement in patients with severe mitral annular calcification using a balloon-expandable valve. Methods: From 2015 to 2023, 82 consecutive patients received mitral annular calcification using a balloon-expandable valve. No patients were excluded from analysis. Patient records were retrospectively reviewed for baseline characteristics, echocardiography results, intraoperative details, postoperative events, and mortality. Results: The cohort was predominantly female (64.6%; 53/82) with a median age of 76 years [interquartile range, 71-80]. Comorbidities including hypertension (92.7%), New York Heart Association class III/IV (59.8%), atrial fibrillation (57.3%), and diabetes (51.2%) were common, contributing to a median Society of Thoracic Surgeons predicted risk of mortality of 5.0% [3.4-8.1]. Sixty-eight patients had moderate or greater mitral stenosis, and 42 patients had moderate or greater regurgitation. The median preoperative mean mitral valve gradient was 8.0 [6.0-11.0] mm Hg, which improved to 5.0 [4.0-6.0] mm Hg postoperatively. Paravalvular leak occurred in 3.7% of patients, with trace/trivial in 7.3%. Severe paravalvular leak requiring intervention occurred in 2 patients (2.4%). There were no instances of valve embolization. The incidence of stroke at 30 days was 4.8%. Thirty-day and 1-year mortality were 13.4% and 23.2%, respectively. Conclusions: Surgical implantation of balloon-expandable valve in the setting mitral annular calcification with low rates of significant paravalvular leak and no left ventricular outflow tract obstruction or valve embolization. This technique represents progress in addressing a challenging surgical condition, although further experience and long-term follow-up are needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.